Clinical statements
Find out what Breast Cancer Care is saying about the latest drug treatments, research papers and health policy issues.
If you’re working on a story and need an expert quote, call us on 0845 092 0807 (out of hours 07702 901 334).
Commenting on new National Institute for Health and Clinical Excellence guidance on the use of opioids as a first-line treatment option to relieve pain for patients receiving palliative care, Dr Emma Pennery, Clinical Director at Breast Cancer Care said:
'Pain can be a significant problem for many people with secondary breast cancer* throughout their illness, from diagnosis through to the palliative care stage. So we support today’s announcement that NICE have issued guidance about...
Responding to draft guidance from The National Institute for Health and Clinical Excellence (NICE) recommending the use of denosumab (Xgeva, Amgen) for patients with bone metastases (where breast cancer has spread to the bones), Tara Beaumont, Clinical Nurse Specialist for secondary breast cancer patients, said:
'We welcome this draft guidance from NICE, which recommends the use of denosumab for patients whose breast cancer has spread to their bones. Currently there are...
Responding to a review of the literature about alcohol and breast cancer which concludes that alcohol is causally related with breast cancer, and at intakes of up to one alcoholic drink (10-12g of ethanol) per day can increase risk, Grete Brauten Smith, Clinical Nurse Specialist at Breast Cancer Care said:
'This review of the literature about the link between alcohol and breast cancer confirms that drinking too much alcohol increases the risk of developing breast cancer,...
Commenting on a paper ‘European cancer mortality predictions for the year 2012’ in the Annals of Oncology which anticipates a substantial reduction in deaths from breast cancer, Jackie Harris, Clinical Nurse Specialist for Breast Cancer Care said:
'It is extremely encouraging to hear that despite growing incidence, breast cancer mortality rates across age groups are predicted to drop significantly in 2012.
'Newer treatments and...
Responding to the National Institute for Health and Clinical Excellence (NICE) draft guidance which proposes to advise the NHS that lapatinib or trastuzumab with aromatase inhibitors should not be prescribed for a particular type and stage of breast cancer, Carolyn Rogers, Clinical Nurse Specialist at Breast Cancer Care said:
'This draft guidance by NICE proposes to advise the NHS that two targeted therapies, lapatinib or trastuzumab,...
- First page
- ››
